&w=3840&q=100)
Aurobindo Pharma stock falls 2% after Q1 results; check key numbers here
At 11:45 PM, Aurobindo Pharma was trading at 2.08 per cent lower at ₹1,067.7 on the NSE. In comparison, the NSE Nifty was trading lower by 0.38 per cent at 24,629.25. The stock has crashed over 31 per cent from its 52-week high of ₹1,592 touched on September 13, 2024. The company's market capitalisation stood at ₹62,261.93 crore.
Aurobindo Pharma Q1 results
Aurobindo Pharma's net profit fell 10.2 per cent year-on-year (Y-o-Y) to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter last year (Q1FY25). The revenue from operations grew 4 per cent Y-o-Y to ₹7,868 crore in Q1FY26, from ₹7,567 crore a year ago.
At the operating level, earnings before interest, tax, depreciation and amortisation (Ebitda) before R&D remained almost flat at ₹1,967 crore compared to ₹1,936 crore in the same quarter of the previous fiscal year. Subsequently, Ebitda margin before R&D declined by 84 bps to 24.8 per cent in Q1FY26, from 25.6 per cent a year ago.
US formulations revenue marginally declined by 1.9 per cent Y-o-Y to ₹3,488 crore, while Europe formulations revenue increased by 18 per cent Y-o-Y to ₹2,338 crore, and growth markets revenue increased by 8.8 per cent Y-o-Y to ₹772 crore.
The company's R&D expenditure for the quarter stood at ₹367 crore, accounting for 4.7 per cent of total revenues. In addition, the company received final approval for 14 Abbreviated New Drug Applications (ANDAs) from the US Food and Drug Administration (FDA) during the quarter.
Aurobindo Pharma dividend
Despite the muted earnings, the company announced an interim dividend of ₹4 per equity share (400 per cent) and fixed August 8, 2025, as the record date. The dividend will be paid on or before August 21, 2025.
About Aurobindo Pharma
Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercialises a wide range of generic pharmaceuticals, branded speciality pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.
The company has 31 manufacturing and packaging facilities that are approved by leading regulatory agencies, including the USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA. The company has a robust product portfolio spread across 7 major therapeutic areas, including CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
an hour ago
- Business Standard
Knowledge Realty Trust (REIT) rallies on debut
Units of Knowledge Realty Trust (REIT) were currently trading at 107.05 on the NSE, a premium of 7.05% compared with the issue price of Rs 100. The scrip was listed at Rs 103, a premium of 3% over the initial public offer (IPO) price. Knowledge Realty Trust (REIT)'s IPO was subscribed 12.48 times. The issue opened for bidding 5 August 2025 and it closed on 7 August 2025. The price band of the IPO is fixed at Rs 95 to 100. The IPO comprised fresh units, aggregating to Rs 4,800 crore. The proceeds from the offer will be utilised towards partial or full repayment or prepayment of certain financial indebtedness of the asset SPVs and the investment entities, amounting to Rs 4,640 crore and general purpose. Ahead of the IPO, Knowledge Realty Trust, on 4 August 2025, raised Rs 1,620 crore from anchor investors. The board allotted 16.20 crore shares at Rs 100 each to 63 anchor investors. The trust had earlier raised Rs 1,200 crore from strategic investors. Knowledge Realty Trust owns and manages a high-quality office portfolio in India. The companys portfolio comprises 29 Grade A office assets totaling 46.3 msf as of March 31, 2025, with 37.1 msf of completed area, 1.2 msf of under-construction area, and 8.0 msf of future development area. The firms portfolio assets house a diversified tenant mix of prominent multinational tenants, including Fortune 500 companies and global capability centers (GCCs), as well as leading domestic corporates. The companys portfolio assets are spread across 6 cities, namely Hyderabad, Mumbai, Bengaluru, Chennai, Gurugram, and GIFT City, Ahmedabad. The firm reported a gross asset value (GAV) of Rs 61,998.9 crore and total portfolio revenue from operations of Rs 39,301.01 crore as on 31 March 2025.
Business Standard
an hour ago
- Business Standard
NSE SME Medistep Healthcare takes a healthy first step, lists at a premium
Shares of Medistep Healthcare was trading at Rs 50.35 on the NSE, a premium of 17.09% compared with the issue price of Rs 43. The scrip was listed at Rs 53, a premium of 23.26% over the initial public offer (IPO) price. The stock is currently frozen at its lower limit of 5% over its listing price. The counter hit a high of Rs 53 and a low of Rs 50.35. About 14.40 lakh shares of the company changed hands at the counter. Medistep Healthcare's IPO was subscribed 356.34 times. The issue opened for bidding on 8 August 2025 and it closed on 12 August 2025. The price of the IPO was set at Rs 43 per share. The IPO comprised fresh issue of 37,44,000 equity shares. The promoter and promoter group shareholding diluted to 68.96% from 93.62% pre-issue. The company intends to utilize the net proceeds for funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility, working capital requirements and general corporate purpose. Medistep Healthcare is a pharmaceutical company that has carved a niche in the Healthcare Industry through its experience in manufacturing Sanitary pads, Energy powder and trading a diverse range of pharmaceutical products, Nutraceutical products, Intimate Products and surgical products through distribution network. As of 20 July 2025, the company had total of 9 employees.
Business Standard
an hour ago
- Business Standard
NSE SME ANB Metal Cast forges a steady debut, shines with premium listing
Shares of ANB Metal Cast IPO was trading at Rs 170 on the NSE, a premium of 8.97% compared with the issue price of Rs 156. The scrip was listed at Rs 164, a premium of 5.13% over the initial public offer (IPO) price. The stock is currently up 3.66% over its listing price. The counter hit a high of Rs 172.20 and a low of Rs 164. About 12.82 lakh shares of the company changed hands at the counter. ANB Metal Cast's IPO was subscribed 1.92 times. The issue opened for bidding on 8 August 2025 and it closed on 12 August 2025. The price band of the IPO was set at Rs 148 to 156 per share. The IPO comprised a fresh issue of 32,00,000 shares. The company intends to utilize the net proceeds for funding capital expenditure requirements for the proposed expansion in existing manufacturing facilities of company by constructing additional floor and installation of additional plant and machineries, part funding long-term working capital requirements and for general corporate purposes. Ahead of the IPO, ANB Metal Cast on 7 August 2025, raised Rs 14.01 crore from anchor investors. The board allotted 8.98 lakh shares at Rs 156 per share to 4 anchor investor. ANB Metal Cast, based in Rajkot, Gujarat, is a leading manufacturer of aluminium extrusions and non-ferrous metal alloys, operating from a 50,000 sq. ft. facility. The company offers a wide range of products including motor bodies, solar profiles, railings, windows, bars, tubes, channels, and customized solutions, catering to industries such as electronics, automotive, solar energy, architecture, and engineering. With a strong footprint across major Indian markets like Delhi, Gujarat, Haryana, Karnataka, Maharashtra, Rajasthan, and Tamil Nadu, ANB Metal Cast is recognized for its precision, reliability, and diverse portfolio spanning industrial, architectural, and kitchen applications. As on 15 July 2025, the company had total 23 employees. The company recorded revenue from operations of Rs 16.25 crore and net profit of Rs 10.24 crore for the period ended 31 March 2025.
